Disease stratification in GCA and PMR: state of the art and future perspectives-Reference-Cited by-同舟云学术

Disease stratification in GCA and PMR: state of the art and future perspectives

Published:2023-06-12 Issue:7 Volume:19 Page:446-459
ISSN:1759-4790
Container-title:Nature Reviews Rheumatology
language:en
Short-container-title:Nat Rev Rheumatol

Author:

Tomelleri Alessandro,van der Geest Kornelis S. M.^ORCID,Khurshid Muhammad Asim,Sebastian Alwin,Coath Fiona,Robbins Daniel,Pierscionek Barbara,Dejaco Christian^ORCID,Matteson Eric,van Sleen Yannick^ORCID,Dasgupta Bhaskar^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

https://www.nature.com/articles/s41584-023-00976-8.pdf

Reference175 articles.

1. Buttgereit, F., Matteson, E. L. & Dejaco, C. Polymyalgia rheumatica and giant cell arteritis. J. Am. Med. Assoc. 324, 993–994 (2020).

2. van der Geest, K. S. M., Sandovici, M., Brouwer, E. & Mackie, S. L. Diagnostic accuracy of symptoms, physical signs, and laboratory tests for giant cell arteritis: a systematic review and meta-analysis. JAMA Intern. Med. 180, 1295–1304 (2020).

3. Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261–271 (2002).

4. Dejaco, C. et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2022-223429 (2023).

5. Matteson, E. L., Buttgereit, F., Dejaco, C. & Dasgupta, B. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum. Dis. Clin. North. Am. 42, 75–90 (2016).

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study;Seminars in Arthritis and Rheumatism;2024-10

2. From polymyalgia arteritica to arteritis polymyalgica: redefining the GCA–PMR spectrum through advanced MRI insights;Rheumatology;2024-09-09

3. Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases;Rheumatology Science and Practice;2024-09-03

4. Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6;Rheumatology Science and Practice;2024-09-02

5. Retrospective Analysis of Specimen Quality in Temporal Artery Biopsies for Giant Cell Arteritis and Disease Association in North Midlands, England;Cureus;2024-08-30